1107620-72-3 Usage
Uses
Used in Pharmaceutical Synthesis:
4-(Boc-aMinoMethyl)pyrazole is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs. Its Boc-protected amino group allows for selective reactions and subsequent deprotection, facilitating the creation of complex molecular structures.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-(Boc-aMinoMethyl)pyrazole is used as a building block for the development of new drugs. Its unique structure and functional groups make it a promising candidate for the design and synthesis of innovative therapeutic agents.
Used in Chemical Research:
4-(Boc-aMinoMethyl)pyrazole is also utilized in chemical research to explore its properties and potential applications. Ongoing research and development in the scientific community aim to uncover new uses and optimize its synthesis for various industries.
The precise properties and uses of 4-(Boc-aMinoMethyl)pyrazole are subject to ongoing research and development, as its potential in various applications continues to be explored and expanded upon.
Check Digit Verification of cas no
The CAS Registry Mumber 1107620-72-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,0,7,6,2 and 0 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1107620-72:
(9*1)+(8*1)+(7*0)+(6*7)+(5*6)+(4*2)+(3*0)+(2*7)+(1*2)=113
113 % 10 = 3
So 1107620-72-3 is a valid CAS Registry Number.
1107620-72-3Relevant articles and documents
SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF
-
Paragraph 00243; 00255; 00256, (2021/09/04)
This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS
-
Page/Page column 171-172, (2009/03/07)
The present invention related to novel heterocyclic amide compounds of Formula 1: as disclosed herein or a pharmaceutically accept able salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosedare compositions comprising said compounds, and methods for using said compounds for treating or preventing a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal disease
